retatrutide type 2 diabetes 🩺 in diabetes: TRANSCEND-T2D-1 Phase 3 results → HbA1c ↓2.0% + weight ↓16.8% at 40 weeks. A triple agonist that tackles both glycemia and obesity simultaneously. 📊💊 Ref: Lilly Weight loss with retatrutide as

New-generation 5-HT4 agonists have high selectivity for 5-HT4 receptors, with little affinity for other serotoninergic and other classes of receptors [53]

You start low

Pancreatitis awareness GLP-1 receptor agonists carry a theoretical risk of pancreatitis, though this has been rare in retatrutide trials specifically

Gong N, Xiao Q, Zhu B, Zhang CY, Wang YC, Fan H et al (2014) Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity

[DOI] [PMC free article] [PubMed] [Google Scholar] 81.Yoon M.J., Yoshida M., Johnson S., Takikawa A., Usui I., Tobe K., Nakagawa T., Yoshino J., Imai S

patients should report any neck mass, difficulty swallowing, or persistent hoarseness